Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
School of Computer Engineering, Iran University of Science and Technology, Tehran, Iran.
Int J Equity Health. 2024 Feb 8;23(1):25. doi: 10.1186/s12939-023-02065-4.
A more equal allocation of healthcare funds for patients who must pay high costs of care ensures the welfare of society. This study aimed to estimate the optimal co-insurance for outpatient drug costs for health insurance.
The research population includes outpatient prescription claims made by the Health Insurance Organization that outpatient prescriptions in a timely manner in 2016, 2017, 2018, and 2019 were utilized to calculate the optimal co-insurance. The study population was representative of the research sample.
At the secondary level of care, 11 features of outpatient claims were studied cross-sectionally and retrospectively using data mining. Optimal co-insurance was estimated using Westerhut and Folmer's utility model.
One hundred ninety-three thousand five hundred fifty-two individuals were created from 21 776 350 outpatient claims of health insurance. Because of cost-sharing, insured individuals in a low-income subsidy plan and those with refractory diseases were excluded.
Insureds were divided into three classes of low, middle, and high risk based on IQR and were separated to three clusters using the silhouette coefficient. For the first, second, and third clusters of the low-risk class, the optimal co-insurance estimates are 0.81, 0.76, and 0.84, respectively. It was equal to one for all middle-class clusters and 0.38, 0.45, and 0.42, respectively, for the high-risk class. The insurer's expenses were altered by $3,130,463, $3,451,194, and $ 1,069,859 profit for the first, second, and third clusters, respectively, when the optimal co-insurance strategy is used for the low-risk class. For middle risks, it was US$29,239,815, US$13,863,810, and US$ 14,573,432 while for high risks, US$4,722,099, US$ 6,339,317, and US$19,627,062, respectively.
These findings can improve vulnerable populations' access to costly medications, reduce resource waste, and help insurers distribute funds more efficiently.
为需支付高额医疗费用的患者公平分配医疗保健资金,以确保社会福利。本研究旨在为医保门诊药品费用制定最佳共付比例。
本研究人群包括及时使用医保 2016、2017、2018 和 2019 年门诊处方的医保组织的门诊处方报销。研究人群代表了研究样本。
在二级护理水平,使用数据挖掘对门诊报销的 11 个特征进行了横断面和回顾性研究。使用 Westerhut 和 Folmer 的效用模型估计最佳共付比例。
从 21776350 份医保门诊报销中创建了 193552 人。由于共付保险,低收入补贴计划的参保人和慢性病患者被排除在外。
参保人根据 IQR 分为低、中、高风险三类,并使用轮廓系数将其分为三个聚类。低风险组第一、二、三聚类的最佳共付比例估计值分别为 0.81、0.76 和 0.84。所有中等风险类别的共付比例均为 1,高风险类别的分别为 0.38、0.45 和 0.42。当低风险类采用最佳共付策略时,对第一、二、三聚类而言,保险公司的费用分别变化了 3130463 美元、3451194 美元和 1069859 美元。对于中等风险,分别为 29239815 美元、13863810 美元和 14573432 美元,对于高风险,分别为 4722099 美元、6339317 美元和 19627062 美元。
这些发现可以改善弱势群体获得昂贵药物的机会,减少资源浪费,并帮助保险公司更有效地分配资金。